Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Neuraxis Inc. (NRXS:NYSE), powered by AI.
Neuraxis Inc. is currently trading at $6.71. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Neuraxis Inc. on Alpha Lenz.
View Neuraxis Inc.'s valuation metrics on Alpha Lenz.
“Neuraxis Inc.'s ROE is -285.4%. Explore profitability and growth together.”
Ask for details →Neuraxis Inc. operates as a biotechnology company focused on the development and commercialization of innovative medical solutions aimed at improving neurological health. Its core mission is to create breakthrough therapies that address various neurological disorders, a field that holds significant importance given the increasing prevalence of such conditions globally. Neuraxis Inc. leverages cutting-edge research and technology to advance treatments in this critical sector, which impacts a wide array of neurological diseases, including but not limited to, neurodegenerative and neurodevelopmental disorders. The company’s work is pivotal in contributing to the broader healthcare and pharmaceutical industries, with particular emphasis on improving patient outcomes and quality of life. Neuraxis Inc.'s position within the biotech landscape highlights its role in driving forward therapeutic innovations and enhancing the understanding and treatment efficacy within neurology. As the demand for advanced neurological treatments continues to grow, Neuraxis Inc. remains at the forefront, influencing the market dynamics with its research-driven approach.
“Neuraxis Inc.'s ROE is -285.4%. Explore profitability and growth together.”
Ask for details →Neuraxis Inc. (ticker: NRXS) is a company listed on NYSE in the Healthcare sector (Biotechnology). It has approximately 21 employees.
The current price is $6.71 with a P/E ratio of -x and P/B of -x.
ROE is -285.36% and operating margin is -219.37%. Annual revenue is $4M.